Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong clinical activity in patients with renal cell carcinomas (RCC) and non-renal cell carcinoma neoplasms associated with von Hippel-Lindau (VHL) disease. The study was published today in the New England Journal of...
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting on radiation-induced immune activation in colorectal cancer, response biomarkers in soft tissue sarcoma, STING-mediated...
The Oden Institute for Computational Engineering and Sciences (Oden Institute), The University of Texas MD Anderson Cancer Center ...
Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...